Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.

MLA

Do, Diana V., et al. “Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.” Ophthalmology, vol. 123, no. 4, Apr. 2016, pp. 850–57. EBSCOhost, https://doi.org/10.1016/j.ophtha.2015.11.008.

APA

Do, D. V., Nguyen, Q. D., Vitti, R., Berliner, A. J., Gibson, A., Saroj, N., Soo, Y., & Boyer, D. S. (2016). Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. Ophthalmology, 123(4), 850–857. https://doi.org/10.1016/j.ophtha.2015.11.008

Chicago

Do, Diana V., Quan Dong Nguyen, Robert Vitti, Alyson J. Berliner, Andrea Gibson, Namrata Saroj, Yuhwen Soo, and David S. Boyer. 2016. “Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti–Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program.” Ophthalmology 123 (4): 850–57. doi:10.1016/j.ophtha.2015.11.008.